SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: chirodoc who wrote (63)	6/10/1998 6:50:00 PM
From: Gwolf	Read Replies (1) of 5402

Chirodoc, I read post #63 where it mentioned Alpha Therapeutics Corp. The article says that this was the first artificial blood product and that it was developed in 1965. It states that in 1979 humans received the first infusions of Flusol-DA, a suspension of clear, oily fluid. The article then goes on to say that after years of doubt the FDA finally approved it for balloon angioplasty. The company made the product from 1989 to 1993. Dr.Drees was the 'President of Alpha Therapeutics'. This company was owned by a Japanese company known as Green Cross. The Japanese doctors had given the blood substitute to a dying patient several months before they were allowed to. The Japanese falsified their documents as to the dates the product was actually introduced so that no one would know about the dying patient being given the blood substitute before they were permitted to do so. These falsified documents were given to the Japanese equivalent of the FDA. They later had a whistle blower tell the Japanese FDA about the falsified date. At this point the Japanese FDA made them take it off of their market. It may not make sense to us but the Japanese felt that they had lost major "Face" so they also removed it from the U.S. market in 1993. The original Fluosol-DA was given to 1500 patients without any deaths or side effects. It was removed from the market, not because it didn't work but because of the problems with the Japanese FDA mentioned above. Dr.Drees has now taken this formally FDA approved product, refined and improved in under the company name Sanquine and the product name PHER-02. Dr. Drees predicted that the other Bovine and Human derivatives would not work because of their toxic nature. One of the causes being the bodies nature to reject the proteins from these derivatives. The original FDA approved product did not exhibit any of these toxic rejection problems. Through various partnerships over the years major players have taken an interest in blood substitutes, they include Upjohn, Ely Lilly and Baxter Healthcare. Each one has tried these unsuccessful products with the one exception being Biopure which has received approval for Oxyglobin for use in animals. This substance has not been used on humans at this point in time. This is again a bovine derivative of the same type that produces toxic results in humans and will produce the same toxic effects if they try to use it on humans. To this date SGNC is the only blood substitute that has received FDA approval (formerly) and has actually been used on over 1500 humans with no deaths or problems. They are now looking to go back through the process as an American company with a refined product, in a market that Former U.S. Surgeon General C. Everett Koop described as "Having the potential to revolutionize the practice of medicine, especially in critical-care situations". I'm no doctor but it seems that this is the one and only viable blood substitute and it's worked before. It's just a matter of time before this is the product that revolutionizes the practice of medicine. Gwolf

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next